After nearly five years of collaboration, Roche and Recursion Pharmaceuticals have something concrete to show for it. On August 5, 2026, the two companies confirmed that their first AI-identified drug target had been advanced, a neuroscience candidate aimed at treating an undisclosed neurodegenerative disease.
The milestone arrived alongside Recursion’s Q2 2026 financial results. It represents the first validated output from a collaboration that has been running since December 2021, when Roche’s biotech subsidiary Genentech signed on to work with Recursion and handed over $150 million upfront to get started.
What the deal actually looks like
The total potential value is up to $12 billion, spread across as many as 40 programs. Each program carries milestone payments of up to $300 million in development and commercialization fees.
The collaboration covers neuroscience primarily, with oncology included as a secondary focus. Recursion CEO Najat Khan pointed to the company’s AI platform, called Recursion OS, as the engine behind the discovery. The platform works by analyzing large-scale datasets built from cellular imaging and genetic perturbation experiments. For this neuroscience target specifically, the analysis drew on whole-genome CRISPR knockout data from neuronal cells. The platform also incorporates a microglial map built from roughly 46 million images, giving it a detailed picture of the immune cells most relevant to neurodegenerative conditions.
